ARS Pharmaceuticals (SPRY) Return on Equity: 2022-2025
Historic Return on Equity for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to -0.53%.
- ARS Pharmaceuticals' Return on Equity fell 24.00% to -0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.53%, marking a year-over-year decrease of 24.00%. This contributed to the annual value of 0.03% for FY2024, which is 25.00% up from last year.
- ARS Pharmaceuticals' Return on Equity amounted to -0.53% in Q3 2025, which was down 89.58% from -0.28% recorded in Q2 2025.
- Over the past 5 years, ARS Pharmaceuticals' Return on Equity peaked at -0.01% during Q4 2024, and registered a low of -0.53% during Q3 2025.
- Moreover, its 3-year median value for Return on Equity was -0.27% (2024), whereas its average is -0.25%.
- As far as peak fluctuations go, ARS Pharmaceuticals' Return on Equity increased by 28bps in 2024, and later declined by 24bps in 2025.
- ARS Pharmaceuticals' Return on Equity (Quarterly) stood at -0.13% in 2022, then fell by 16bps to -0.29% in 2023, then increased by 28bps to -0.01% in 2024, then fell by 24bps to -0.53% in 2025.
- Its last three reported values are -0.53% in Q3 2025, -0.28% for Q2 2025, and -0.11% during Q1 2025.